NDA 209445 · Shionogi
Fetroja
Cefiderocol Sulfate Tosylate · Intravenous
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jul 1, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Nov 14, 2019
Approved uses
2
Original approval plus efficacy supplements
Registered trials
19
3 Phase 3, 3 recruiting
FAERS reports
315
282 serious, 147 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 24, 2026.
FETROJA is a cephalosporin antibacterial indicated in patients 18 years of age or older for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Complicated Urinary Tract Infections (cUTI), including Pyelonephritis ( 1.1 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of FETROJA and other antibacterial drugs, FETROJA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) 1.1 Complicated Urinary Tract Infections (cUTIs), Including Pyelonephritis FETROJA ® is indicated in patients 18 years of age or older for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis caused by the following susceptible Gram-negative microorganisms: Escherichia coli , Klebsiella pneumoniae , Proteus mirabilis , Pseudomonas aeruginosa , and Enterobacter cloacae complex [see Clinical Studies (14.1) ] . 1.2 Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) FETROJA is indicated in patients 18 years of age or older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, caused by the following susceptible Gram-negative microorganisms: Acinetobacter baumannii complex, Escherichia coli , Enterobacter cloacae complex, Klebsiella pneumoniae , Pseudomonas aeruginosa , and Serratia marcescens [see Clinical Studies (14.2) ]. 1.3 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of FETROJA and other antibacterial drugs, FETROJA should be used only to treat or prevent infections that are proven...
Mechanism: FETROJA is an antibacterial drug [see Microbiology (12.4) ] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 25, 2020 Supplement 2 · Efficacy · priority review LabelLetterReview
- Nov 14, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
1 products under this application
- FETROJA · CEFIDEROCOL SULFATE TOSYLATE EQ 1GM BASE/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cefiderocol" as an intervention, any sponsor and status, largest first.
Rambam Health Care CampusAcademic, hospital or other
NCT05922124 · 734 participants (planned) · Start Sep 1, 2024 · Primary completion Jul 2026
Drug: Cefiderocol; Ampicillin-sulbactam and 2 more · For: Carbapenem Resistant Bacterial Infection; Acinetobacter Bacteremia; Acinetobacter Pneumonia
Sites: Haifa, Israel; Ramat Gan, Israel; Tel Aviv, Israel
- Optimising TREATment for Severe Gram-Negative Bacterial InfectionsPivotal-lookingRecruiting
National University of SingaporeAcademic, hospital or other
NCT07004049 · 600 participants (planned) · Start Apr 21, 2025 · Primary completion Dec 31, 2028
Drug: Colistin/Polymyxin B + Sulbactam; Colistin/Polymyxin B + Tigecycline/Eravacycline and 12 more · For: Bloodstream Infection; Ventilator Associated Bacterial Pneumonia; Hospital Acquired Bacterial Pneumonia and 2 more
Sites: Brisbane, Australia; Hangzhou, China; Xi'an, China · 41 sites in all
- RCT Cefiderocol vs BAT for Treatment of Gram Negative BSIPivotal-lookingCompleted
The University of QueenslandAcademic, hospital or other
NCT03869437 · 513 participants · Start Oct 28, 2019 · Primary completion Nov 13, 2023
Drug: Cefiderocol · For: Bloodstream Infections
Sites: Sydney, Australia; Brisbane, Australia; Melbourne, Australia · 19 sites in all
- A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract InfectionsPivotal-lookingCompleted
ShionogiIndustry
NCT02321800 · 452 participants · Start Feb 5, 2015 · Primary completion Jul 26, 2016
Drug: Cefiderocol; Imipenem/cilastatin · For: Urinary Tract Infections
- Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative PathogensPivotal-lookingCompleted
ShionogiIndustry
NCT03032380 · 300 participants · Start Oct 24, 2017 · Primary completion Feb 26, 2019
Drug: Cefiderocol; Meropenem and 1 more · For: Healthcare-associated Pneumonia (HCAP); Hospital Acquired Pneumonia (HAP); Ventilator Associated Pneumonia (VAP)
Sites: New Haven, Connecticut; DeLand, Florida; Chicago, Illinois · 119 sites in all
- Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver TransplantationPivotal-lookingNot yet recruiting
IRCCS Azienda Ospedaliero-Universitaria di BolognaAcademic, hospital or other
NCT07759453 · 168 participants (planned) · Start Oct 1, 2026 · Primary completion Jun 30, 2029
Drug: Ceftazidime - Avibactam ( CAZ-AVI); Meropenem-Vaborbactam and 8 more · For: Liver Transplant; Carbapenem-resistant Enterobacterales; CRE Colonization
Sites: Bologna, Italy; Pisa, Italy; Torino, Italy
- Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative PathogensPivotal-lookingCompleted
ShionogiIndustry
NCT02714595 · 152 participants · Start Sep 7, 2016 · Primary completion Apr 1, 2019
Drug: Cefiderocol; Best Available Therapy · For: Healthcare-associated Pneumonia (HCAP); Bloodstream Infections (BSI); Hospital Acquired Pneumonia (HAP) and 3 more
Sites: Hartford, Connecticut; Newark, Delaware; Chicago, Illinois · 85 sites in all
- Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus ComplexPivotal-lookingNot yet recruiting
BioVersys AGIndustry
NCT07431307 · 120 participants (planned) · Start Jul 2026 · Primary completion Mar 2028
Drug: BV100 with 50 mg polymyxin B plus ceftazidime/avibactam; BV100 with 50 mg polymyxin B plus cefiderocol and 1 more · For: Ventilator Associated Bacterial Pneumonia (VABP); Hospital Acquired Bacterial Pneumonia (HABP); Blood Stream Infection and 2 more
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death71
- drug resistance31
- treatment failure27
- off label use26
- acute kidney injury23
- pathogen resistance17
- hepatic cytolysis14
- multiple organ dysfunction syndrome14
- infection13
- cholestasis12
- condition aggravated11
- septic shock11
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 11 |
| 2021 | 32 |
| 2022 | 71 |
| 2023 | 82 |
| 2024 | 68 |
| 2025 | 33 |
| 2026 | 18 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Fetroja (Cefiderocol Sulfate Tosylate)
2024 spending
$6.9M
Beneficiaries
345
1,794 claims
Per beneficiary
$20,073
$24.32 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $145,378 |
| 2021 | $1,965,494 |
| 2022 | $2,150,962 |
| 2023 | $4,298,680 |
| 2024 | $6,925,287 |
Part B: Fetroja (Cefiderocol Sulfate Tosylate) · HCPCS J0699
2024 spending
$43K
Beneficiaries
24
27 claims
Per beneficiary
$1,812
2024 ASP limit $2.22 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $30,639 |
| 2022 | $182,277 |
| 2023 | $76,802 |
| 2024 | $43,498 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M, Echols R, Matsunaga Y, et al. · Lancet Infect Dis 2021 · Clinical Trial, Phase III, Multicenter Study
- Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial.
Paterson DL, Sulaiman H, Liu PY, et al. · Lancet Infect Dis 2026 · Randomized Controlled Trial, Multicenter Study
- Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: A systematic review and meta-analysis.
Onorato L, de Luca I, Monari C, et al. · J Infect 2024 · Meta-Analysis, Systematic Review
- Drug-resistant Acinetobacter baumannii: mortality, emerging treatments, and future pharmacological targets for a WHO priority pathogen.
Dubey V, Reza N, Hope W · Clin Microbiol Rev 2025 · Systematic Review
- Efficacy of treatment options for complicated urinary tract infections including acute pyelonephritis: a systematic literature review and network meta-analysis.
Wagenlehner F, Caballero VR, Maheshwari V, et al. · J Comp Eff Res 2025 · Systematic Review, Network Meta-Analysis
- Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.
Wunderink RG, Matsunaga Y, Ariyasu M, et al. · Lancet Infect Dis 2021 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Shionogi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.